INO 1001

Drug Profile

INO 1001

Alternative Names: INO-1001; Pardex; PARP inhibitors - Inotek

Latest Information Update: 11 Jan 2011

Price : $50

At a glance

  • Originator Inotek Pharmaceuticals
  • Developer Genentech; Inotek Pharmaceuticals
  • Class Indoles; Vasoprotectives
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Reperfusion injury
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Abdominal aortic aneurysm; Acute lung injury; Erectile dysfunction; Glioblastoma; Malignant melanoma; Reperfusion injury

Most Recent Events

  • 11 Jan 2011 Discontinued - Phase-I for Abdominal aortic aneurysm in USA (Parenteral)
  • 11 Jan 2011 INO 1001 is available for licensing as of 11 Jan 2011. http://www.inotekcorp.com
  • 27 Mar 2007 Data presented at the 56th Annual Scientific Session of the American College of Cardiology (ACC-2007) added to the adverse events and Ischaemic Heart Disease pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top